The HER2+ breast cancer subtype that constitutes 15–20% of invasive breast cancers has an amplification/activation of the HER2 gene which results in overexpression of the HER2 receptor on the surface of breast cancer cells [2,3]. The gene discussed is ERBB2; the disease is breast carcinoma.